Since this month of November, a new pharmacological alternative financed by the National Health System to quit smoking has been available in Spain. Is about The restwhose active ingredient is cytisynicline. According to its package insert, it “allows a gradual reduction in nicotine dependence without withdrawal symptoms.”
According to Noa Rey, a pharmacist specializing in smoking and member of the Board of Directors of the National Committee for the Prevention of Smoking (CNPT), Recigarum joins other pharmacological products already available for smoking cessation.
The product that has just been financed by the Public Health Service is in fact based on the same active principle as Todacitanwhich is also funded from the beginning of 2023. Both are indicated under medical prescription.
“Both are very effective treatments for quitting smoking that have been marketed in other European countries for decades and have demonstrated their safety and effectiveness,” says Rey. According to the specialist, cytisinicline was already used in World War II to treat withdrawal syndrome in combatants.
“It is undoubtedly good news to have another funded treatment to quit smoking because it has been shown that financing treatments increases the number of people who are going to try to quit smoking,” he emphasizes. Additionally, he adds, funding also helps reduce inequalities in access.